Implications of transmission with undetectable HIV viral load: lower limit...
Simon Collins, HIV i-Base An Australian research group, led by David Wilson from the University of New South Wales, Sydney, published a study in the Lancet modelling the potential impact of a low-level...
View ArticleMaking progress on prevention
A TAC policy briefing A goal of the HIV & AIDS and STI Strategic Plan for South Africa 2007-2011 (NSP) is to reduce new infections by half over the five-year period of the plan. Is it difficult to...
View ArticleTreatment reduces infections by over 90%: a theme that is here to stay
Simon Collins, HIV i-Base CROI was important this year because of the profile given to further studies supporting the role of treatment as prevention. Together they support the argument that universal...
View ArticleTrial finds high adverse event rate of circumcision device being marketed in...
Nathan Geffen, TAC Orange Farm, a township about 40 kilometres from Johannesburg, was the site of one of three randomised controlled trials that demonstrated that medical circumcision reduces the risk...
View ArticleUS CDC issue preliminary guidance for use of PrEP
Simon Collins, HIV i-Base On 27 January 2011 the US Centre for Disease Control (CDC) issued preliminary guidance for the use of tenofovir/FTC (Truvada) as primary prophylaxis against HIV infection for...
View ArticlePre-exposure prophylaxis (PrEP) with tenofovir/FTC reduces sexual...
Simon Collins, HIV i-Base The published results and the supportive supplementary appendix from a large international study (conducted in Peru, Equador, Brazil, US, Thailand and South Africa) provide...
View ArticleMale circumcision retains effectiveness at reducing risk of HIV infection: 54...
Nathan Geffen, TAC A late breaker by Bailey and Colleagues presented at the International AIDS Conference reported on the follow-up to the randomised male medical circumcision trial conducted in...
View ArticleResults from the Caprisa 004 tenofovir microbicide trial
Simon Collins, HIV i-Base In terms of conference headlines, the biggest news came from the results of a prevention study called Caprisa 004. This study reported that a microbicide gel containing 1%...
View ArticleFEM-PrEP prevention study using daily Truvada halted during enrollment:...
On 18 April a press statement from Family Health International announced that the FEM-PrEP study had been stopped by the trials Independent Data Monitoring Committee (IDMC) due to an interim analysis...
View ArticleHPTN 052 study stopped early: significant reduction in HIV transmission from...
Although more detailed results have since been presented (see earlier report from IAS Rome conference earlier in this issue), the following summary information was reported as a press release from the...
View ArticleTenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from...
Simon Collins, HIV i-Base The final presentation in the Treatment is Prevention session was a summary of the first results from the Partners PrEP study that randomised the HIV-negative partner in 4758...
View ArticleDaily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the...
Simon Collins, HIV i-Base Results from the double-blind placebo-controlled TDF2 study presented in an oral presentation in Rome provided additional supportive data for the benefit of daily oral...
View ArticleTreatment is prevention: ARV treatment in HPTN-052 reduces transmission by at...
Simon Collins, HIV i-Base Four of the six oral presentations in the ‘Treatment is prevention: the proof is here’ session reported on the results from HPTN 052. [1] This study had been unblinded four...
View ArticleDSMB stops oral tenofovir monotherapy arm of VOICE PrEP study due to lack of...
Research into the use of tenofovir as daily prophylaxisis to prevent HIV infection (PrEP) was further complicated by news that one of the key ongoing studies has discontinued women using tenofovir as...
View ArticleOrange Farm circumcision results dispel concerns about risk compensation
Nathan Geffen, TBonline Amidst the excitement about HPTN 052 at the Rome IAS meeting, the results of the ANRS Orange Farm circumcision programme received little publicity, despite stunning data. Orange...
View ArticleFDA approve Truvada to reduce the risk of sexual transmission
FDA press release On 16 July 2012, the US Food and Drug Administration approved Truvada (tenofovir/FTC) to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV...
View ArticleMechanisms for circumcision to reduce HIV transmission in different penile...
Simon Collins, HIV i-Base An intensive study looking at the protective impact on adult male circumcision for reducing the risk of sexual HIV transmission suggested new biological mechanisms for...
View ArticleHigh levels of maraviroc in rectal tissue fail to protect macaques from SIV...
Simon Collins, HIV i-Base A poster from the group responsible for key animal PK studies looking at tenofovir and/or FTC for PrEP presented a poster with disappointing findings with maraviroc. These...
View ArticleOnline video interviews between researchers and activists
Simon Collins, HIV i-Base The US activist Fred Schaich has for many years persuaded leading researchers and other activists attending key medical meetings to step away from the main meeting and spend...
View ArticleHPTN-052: clinical advantages from earlier treatment
Simon Collins, HIV i-Base A late breaker oral presentation from the HPTN-052 study was widely reported from IAS this year, with the simple conclusion that it added to the evidence supporting clinical...
View Article
